

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SAMSUNG BIOEPIS CO. LTD, BIOCON BIOLOGICS INC.

Petitioner(s),

v.

REGENERON PHARMACEUTICALS, INC.,

Patent Owner.

IPR2023-00739

Patent 10,888,601 B2¹

Before JOHN G. NEW and RYAN H. FLAX, *Administrative Patent Judges*.

PER CURIAM

ORDER

Conduct of the Proceeding

Canceling Oral Argument

37 C.F.R. §§ 42.54, 42.70

¹ IPR2024-00201 has been joined with IPR2023-00739.

Oral argument in this case was set for on July 24, 2024 at 10:00 a.m. EDT in Hearing Room A, on the ninth floor of Madison Building East, 600 Dulany Street, Alexandria, Virginia. Paper 52. On July 10, 2024, Patent Owner Regeneron Pharmaceuticals, Inc. (“Patent Owner”) communicated to the panel, *via* email, that it had filed a Disclaimer under 37 C.F.R. § 1.321(a), disclaiming claims 10–12, 17–19, 21, 25–28, and 33 of U.S. Patent No. 10,888,601 B2 that are the subject of this *inter partes* review. *See* Ex. 3002. A copy of the Disclaimer was attached to the email, and is entered as Exhibit 3003. Patent Owner also informed the Board that it had previously disclaimed all other claims challenged in this proceeding. *See* Exs. 2001, 2002.

Because no challenged claims remain in this *inter partes* review, Patent Owner requested termination of the proceeding. An order concerning termination of the proceeding will be forthcoming in due course. In the meantime, the oral argument scheduled for July 24, 2002 is canceled as moot.

IT IS SO ORDERED

IPR2023-00739
Patent 10,888,601 B2

For PETITIONER:

Raymond Nimrod
Matthew Traupman
Landon Smith
QUINN EMANUEL URQUHART & SULLIVAN, LLP
raynimrod@quinnemanuel.com
matthewtraupman@quinnemanuel.com
landonsmith@quinnemanuel.com

For PATENT OWNER:

Adam Brausa
Rebecca Weires
Kira Davis
Daralyn Durie
MORRISON & FOERSTER LLP
abrausa@mofo.com
rweires@mofo.com
kiradavis@mofo.com
ddurie@mofo.com